Also Known as "The Sleep Cannabinoid", Cannabinol (CBN) Is Now Available in Commercial Quantities

This rare cannabinoid is taking the wellness and CBD markets by storm as new research and anecdotal evidence expands

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2020) - FloraWorks Holdings Inc. ("FloraWorks" or the "Company") Cannabinol (CBN), the rare cannabinoid often only found in trace amounts of aged cannabis has been shown to have unique physiological effects that have already started gaining traction for consumer health applications. FloraWorks is excited to announce that after significant research and development efforts, the Company is now manufacturing highly-pure, hemp-derived CBN isolate at scale, that is now commercially available for sale.

FloraWorks strives to be the cannabinoid enterprise of the future. With its cutting edge research, forward-thinking technology and scaled cannabinoid production, the Company provides products manufacturers with pharmaceutical-grade cannabinoid ingredient formulations for use in a wide variety of consumer applications.

Despite being new to the market, FloraWorks has already partnered with market leading CBD consumer brands to bolster product formulations with CBN amongst other cannabinoids. The ability to provide CBN at scale and high purity has allowed rapid growth in a variety of consumer applications including tinctures, gummies, chocolates, beverages, topicals and more.

FloraWorks exists to empower the innovators. For those interested in taking advantage of this new opportunity please go to www.flora-works.com to learn more and reach out to one of our Partnership Representatives.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7206/57506_a4b74649c47d2af0_002.jpg

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7206/57506_a4b74649c47d2af0_002full.jpg

"Since inception, FloraWork's primary focus has been the production of Cannabinol. We believe CBN has the potential to be the most important hemp-derived cannabinoid to hit the market due to its unique attributes and potential for use in a wide range of wellness products. At FloraWorks, our initial goal was to provide a reliable high-quality supply of CBN to the industry." - Alan Ridgeway, Chief Executive Officer

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7206/57506_a4b74649c47d2af0_003.jpg

Figure 2

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/7206/57506_a4b74649c47d2af0_003full.jpg

"We have put together a team committed to taking the extra steps to do this right. Our vision is bigger than simply unlocking new science and techniques in our industry; it extends to working with partners in the industry to help produce high-quality products that consumers trust to help improve their overall wellness. You will see that vision woven into the fabric of everything we do, including the launch of our own consumer-facing products expected later this year." - Alleh Lindquist, Chief Strategic Officer

At FloraWorks we are constantly pairing the latest science and technologies to our industry, however, our vision goes beyond being a leader in cannabinoid refinement.

About FloraWorks

Bringing Innovation to life through excellence in partnership.

FloraWorks is a specialized supplier of hemp-derived cannabinoids for use in a wide variety of consumer and enterprise applications. We leverage forward-thinking technology, research, and attention to our customers' needs to unlock the economic and therapeutic opportunities of these unique cannabinoid compounds, harnessing their power for good.

Forward-Looking Statements

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, ultimate clinical outcomes, and benefit of the Company's products, market acceptance of the Company's products, intellectual property protection, competitive product offerings, adverse changes in the public perception of cannabis, adverse changes in applicable laws and adverse changes in the application or enforcement of current laws, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company's securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information regarding FloraWorks please contact:

Alan Ridgeway, CEO
FloraWorks Holding Inc.
alan@flora-works.com

Source FloraWorks Media: ( https://flora-works.com/media-kit/ )

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57506

info